TF and cancer: Another ADC called TF-011-MMAE, a compound of human TF-specific mAb conjugated to MMAE by a protease-cleavable linker, is able to interrupt TF:FVIIa-dependent intracellular signaling and eliminates cancer cells in vivo without affecting TF procoagulant activity in many solid tumors.